Xiaobin Wu Sells 4,500 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 4,500 shares of the stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $200.14, for a total transaction of $900,630.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, September 17th, Xiaobin Wu sold 500 shares of BeiGene stock. The shares were sold at an average price of $200.00, for a total transaction of $100,000.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The shares were sold at an average price of $189.65, for a total transaction of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total transaction of $233,133.61.

BeiGene Price Performance

NASDAQ:BGNE opened at $201.99 on Friday. The company has a 50-day moving average of $182.24 and a 200-day moving average of $164.45. The company has a market capitalization of $19.57 billion, a price-to-earnings ratio of -26.68 and a beta of 0.61. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $215.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The firm had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. During the same quarter last year, the company posted ($3.64) EPS. The company’s quarterly revenue was up 56.1% compared to the same quarter last year. As a group, equities research analysts anticipate that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BGNE. Capital International Investors lifted its stake in BeiGene by 11.5% in the first quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after buying an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after acquiring an additional 117,905 shares in the last quarter. Capital International Inc. CA grew its holdings in BeiGene by 6.0% during the first quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock worth $134,240,000 after purchasing an additional 48,615 shares during the period. Point72 Asset Management L.P. bought a new position in BeiGene during the second quarter worth about $54,412,000. Finally, First Trust Advisors LP bought a new stake in shares of BeiGene during the fourth quarter worth approximately $39,632,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

BGNE has been the subject of a number of research reports. Citigroup lifted their price objective on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. JMP Securities initiated coverage on shares of BeiGene in a research note on Wednesday. They set a “market outperform” rating and a $288.00 price objective on the stock. JPMorgan Chase & Co. boosted their price target on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, Bank of America dropped their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $241.21.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.